What's in Janssen Biotech, Inc.'s pipeline?

Janssen Biotech, Inc. has 5 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 5 in Phase 2, 0 in Phase 1.

Which companies overlap with Janssen Biotech, Inc.'s portfolio?

Top competitors by shared drug class: AbbVie (prior sponsor, Abbott), Abbott, Altuğ Güner, Alvotech Swiss AG, Asan Medical Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/janssen-biotech-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Janssen Biotech, Inc. — Portfolio Competitive Intelligence Brief

Janssen Biotech, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 5 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AbbVie (prior sponsor, Abbott) · 1 shared drug class
Abbott · 1 shared drug class
Altuğ Güner · 1 shared drug class
Alvotech Swiss AG · 1 shared drug class
Asan Medical Center · 1 shared drug class
Assistance Publique Hopitaux De Marseille · 1 shared drug class
Bio-Thera Solutions · 1 shared drug class
ASIS Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Janssen Biotech, Inc.:

Cite this brief

Drug Landscape (2026). Janssen Biotech, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/janssen-biotech-inc. Accessed 2026-05-16.